Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264

Alan P. Venook, Merrill J. Egorin, Gary L. Rosner, Thomas D. Brown, Thierry M. Jahan, Gerald Batist, Raymond Hohl, Daniel Budman, Mark J. Ratain, Christine M. Kearns, Richard L. Schilsky

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: To characterize the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmocokinetics of paclitaxel in patients with abnormal liver function. Patients and Methods: Adults with tumors appropriate for paclitaxel therapy who had abnormal liver function tests were eligible. Patients were assigned to one of three treatment cohorts: I, AST level twofold normal and bilirubin level less than 1.5 mg/dL; II, bilirubin level 1.6 to 3.0 mg/dL; and III, bilirubin level greater than 3.0 mg/dL. Doses were explored in at least three patients within each cohort. Although designed to assess a 24-hour infusion schedule, the trial was extended to also assess a 3-hour regimen. Pharmacokinetics were to be studied in all patients. Results: Eighty-one patients were assessable for toxicity. Patients with bilirubin levels greater than 1.5 mg/dL had substantial toxicity at all doses explored, whereas the toxicity for patients with elevated AST levels occurred at doses that ranged from 50 to 175 mg/m2 administered over 24 hours. In most patients, the DLT was myelosuppression. The pharmacokinetic data were insufficient to adequately evaluate the relationship between pharmacokinetics and toxicity in patients who received 24-hour infusions but provided evidence of o longer exposure to paclitaxel than anticipated for the doses used in this study in the 3-hour infusion group. Conclusion: If paclitaxel is used for patients with elevated levels of AST or bilirubin, dose reductions are necessary, and on increase in toxicity can be anticipated. The increased myelosuppression observed is at least partially because of altered paclitaxel pharmacokinetics in such patients.

Original languageEnglish (US)
Pages (from-to)1811-1819
Number of pages9
JournalJournal of Clinical Oncology
Volume16
Issue number5
DOIs
StatePublished - Jan 1 1998

Fingerprint

Liver Neoplasms
Paclitaxel
Leukemia
Pharmacokinetics
Bilirubin
Maximum Tolerated Dose
Liver Function Tests
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Venook, A. P., Egorin, M. J., Rosner, G. L., Brown, T. D., Jahan, T. M., Batist, G., ... Schilsky, R. L. (1998). Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264. Journal of Clinical Oncology, 16(5), 1811-1819. https://doi.org/10.1200/JCO.1998.16.5.1811
Venook, Alan P. ; Egorin, Merrill J. ; Rosner, Gary L. ; Brown, Thomas D. ; Jahan, Thierry M. ; Batist, Gerald ; Hohl, Raymond ; Budman, Daniel ; Ratain, Mark J. ; Kearns, Christine M. ; Schilsky, Richard L. / Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction : Cancer and leukemia group B 9264. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 5. pp. 1811-1819.
@article{48b5bdd65389418f81bd4f72d90d22ac,
title = "Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264",
abstract = "Purpose: To characterize the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmocokinetics of paclitaxel in patients with abnormal liver function. Patients and Methods: Adults with tumors appropriate for paclitaxel therapy who had abnormal liver function tests were eligible. Patients were assigned to one of three treatment cohorts: I, AST level twofold normal and bilirubin level less than 1.5 mg/dL; II, bilirubin level 1.6 to 3.0 mg/dL; and III, bilirubin level greater than 3.0 mg/dL. Doses were explored in at least three patients within each cohort. Although designed to assess a 24-hour infusion schedule, the trial was extended to also assess a 3-hour regimen. Pharmacokinetics were to be studied in all patients. Results: Eighty-one patients were assessable for toxicity. Patients with bilirubin levels greater than 1.5 mg/dL had substantial toxicity at all doses explored, whereas the toxicity for patients with elevated AST levels occurred at doses that ranged from 50 to 175 mg/m2 administered over 24 hours. In most patients, the DLT was myelosuppression. The pharmacokinetic data were insufficient to adequately evaluate the relationship between pharmacokinetics and toxicity in patients who received 24-hour infusions but provided evidence of o longer exposure to paclitaxel than anticipated for the doses used in this study in the 3-hour infusion group. Conclusion: If paclitaxel is used for patients with elevated levels of AST or bilirubin, dose reductions are necessary, and on increase in toxicity can be anticipated. The increased myelosuppression observed is at least partially because of altered paclitaxel pharmacokinetics in such patients.",
author = "Venook, {Alan P.} and Egorin, {Merrill J.} and Rosner, {Gary L.} and Brown, {Thomas D.} and Jahan, {Thierry M.} and Gerald Batist and Raymond Hohl and Daniel Budman and Ratain, {Mark J.} and Kearns, {Christine M.} and Schilsky, {Richard L.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.5.1811",
language = "English (US)",
volume = "16",
pages = "1811--1819",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

Venook, AP, Egorin, MJ, Rosner, GL, Brown, TD, Jahan, TM, Batist, G, Hohl, R, Budman, D, Ratain, MJ, Kearns, CM & Schilsky, RL 1998, 'Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264', Journal of Clinical Oncology, vol. 16, no. 5, pp. 1811-1819. https://doi.org/10.1200/JCO.1998.16.5.1811

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction : Cancer and leukemia group B 9264. / Venook, Alan P.; Egorin, Merrill J.; Rosner, Gary L.; Brown, Thomas D.; Jahan, Thierry M.; Batist, Gerald; Hohl, Raymond; Budman, Daniel; Ratain, Mark J.; Kearns, Christine M.; Schilsky, Richard L.

In: Journal of Clinical Oncology, Vol. 16, No. 5, 01.01.1998, p. 1811-1819.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction

T2 - Cancer and leukemia group B 9264

AU - Venook, Alan P.

AU - Egorin, Merrill J.

AU - Rosner, Gary L.

AU - Brown, Thomas D.

AU - Jahan, Thierry M.

AU - Batist, Gerald

AU - Hohl, Raymond

AU - Budman, Daniel

AU - Ratain, Mark J.

AU - Kearns, Christine M.

AU - Schilsky, Richard L.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: To characterize the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmocokinetics of paclitaxel in patients with abnormal liver function. Patients and Methods: Adults with tumors appropriate for paclitaxel therapy who had abnormal liver function tests were eligible. Patients were assigned to one of three treatment cohorts: I, AST level twofold normal and bilirubin level less than 1.5 mg/dL; II, bilirubin level 1.6 to 3.0 mg/dL; and III, bilirubin level greater than 3.0 mg/dL. Doses were explored in at least three patients within each cohort. Although designed to assess a 24-hour infusion schedule, the trial was extended to also assess a 3-hour regimen. Pharmacokinetics were to be studied in all patients. Results: Eighty-one patients were assessable for toxicity. Patients with bilirubin levels greater than 1.5 mg/dL had substantial toxicity at all doses explored, whereas the toxicity for patients with elevated AST levels occurred at doses that ranged from 50 to 175 mg/m2 administered over 24 hours. In most patients, the DLT was myelosuppression. The pharmacokinetic data were insufficient to adequately evaluate the relationship between pharmacokinetics and toxicity in patients who received 24-hour infusions but provided evidence of o longer exposure to paclitaxel than anticipated for the doses used in this study in the 3-hour infusion group. Conclusion: If paclitaxel is used for patients with elevated levels of AST or bilirubin, dose reductions are necessary, and on increase in toxicity can be anticipated. The increased myelosuppression observed is at least partially because of altered paclitaxel pharmacokinetics in such patients.

AB - Purpose: To characterize the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmocokinetics of paclitaxel in patients with abnormal liver function. Patients and Methods: Adults with tumors appropriate for paclitaxel therapy who had abnormal liver function tests were eligible. Patients were assigned to one of three treatment cohorts: I, AST level twofold normal and bilirubin level less than 1.5 mg/dL; II, bilirubin level 1.6 to 3.0 mg/dL; and III, bilirubin level greater than 3.0 mg/dL. Doses were explored in at least three patients within each cohort. Although designed to assess a 24-hour infusion schedule, the trial was extended to also assess a 3-hour regimen. Pharmacokinetics were to be studied in all patients. Results: Eighty-one patients were assessable for toxicity. Patients with bilirubin levels greater than 1.5 mg/dL had substantial toxicity at all doses explored, whereas the toxicity for patients with elevated AST levels occurred at doses that ranged from 50 to 175 mg/m2 administered over 24 hours. In most patients, the DLT was myelosuppression. The pharmacokinetic data were insufficient to adequately evaluate the relationship between pharmacokinetics and toxicity in patients who received 24-hour infusions but provided evidence of o longer exposure to paclitaxel than anticipated for the doses used in this study in the 3-hour infusion group. Conclusion: If paclitaxel is used for patients with elevated levels of AST or bilirubin, dose reductions are necessary, and on increase in toxicity can be anticipated. The increased myelosuppression observed is at least partially because of altered paclitaxel pharmacokinetics in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0031832839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031832839&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.5.1811

DO - 10.1200/JCO.1998.16.5.1811

M3 - Article

C2 - 9586895

AN - SCOPUS:0031832839

VL - 16

SP - 1811

EP - 1819

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -